202 related articles for article (PubMed ID: 29099349)
1. CFTR Modulator Therapy for Cystic Fibrosis.
Grasemann H
N Engl J Med; 2017 Nov; 377(21):2085-2088. PubMed ID: 29099349
[No Abstract] [Full Text] [Related]
2. Triple CFTR Modulator Therapy for Cystic Fibrosis.
Holguin F
N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
[No Abstract] [Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
4. CFTR mutations and cystic fibrosis.
Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
[No Abstract] [Full Text] [Related]
5. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
6. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
7. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
8. A little CFTR can change a lot: slowing cystic fibrosis progression.
Rowe SM
Lancet Respir Med; 2017 Feb; 5(2):86-87. PubMed ID: 28011036
[No Abstract] [Full Text] [Related]
9. Entering the era of highly effective CFTR modulator therapy.
Zemanick ET; Accurso FJ
Lancet; 2019 Nov; 394(10212):1886-1888. PubMed ID: 31679947
[No Abstract] [Full Text] [Related]
10. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
11. Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery in adult patients with cystic fibrosis.
Tagliati C; Lanni G; Battista D; Pantano S; Ripani P
Clin Otolaryngol; 2024 Mar; 49(2):243-246. PubMed ID: 37933411
[No Abstract] [Full Text] [Related]
12. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
13. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
14. Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation. Reply.
Jain R; Middleton PG; Rowe SM
N Engl J Med; 2020 Feb; 382(7):684. PubMed ID: 32053311
[No Abstract] [Full Text] [Related]
15. A new era has dawned for persons with cystic fibrosis; however many knowledge gaps exist in our efforts to improve care.
Hadjiliadis D; Clausen ES
J Cyst Fibros; 2022 May; 21(3):383-384. PubMed ID: 35437232
[No Abstract] [Full Text] [Related]
16. Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del.
Beswick DM; Humphries SM; Balkissoon CD; Strand M; E Miller J; Khatiwada A; Vladar EK; Lynch DA; Taylor-Cousar JL
Int Forum Allergy Rhinol; 2022 Jul; 12(7):963-966. PubMed ID: 34908251
[No Abstract] [Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
18. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
19. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
20. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
Antoniu SA
Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]